{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:44:13Z","timestamp":1792086253097,"version":"4.4.0"},"reference-count":45,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs) have substantially improved overall survival in patients with advanced melanoma; however, the lack of biomarkers to monitor treatment response and relapse remains an important clinical challenge. Thus, a reliable biomarker is needed that can risk\u2010stratify patients for disease recurrence and predict response to treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis using a personalized, tumor\u2010informed circulating tumor DNA (ctDNA) assay on prospectively collected plasma samples (<jats:italic>n<\/jats:italic>\u00a0=\u00a0555) from 69 patients with advanced melanoma was performed. Patients were divided into three cohorts: cohort A (<jats:italic>N<\/jats:italic>\u00a0=\u00a030), stage III patients receiving adjuvant ICI\/observation; cohort B (<jats:italic>N<\/jats:italic>\u00a0=\u00a029), unresectable stage III\/IV patients receiving ICI therapy; and cohort C (<jats:italic>N<\/jats:italic>\u00a0=\u00a010), stage III\/IV patients on surveillance after planned completion of ICI therapy for metastatic disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In cohort A, compared to molecular residual disease (MRD)\u2010negative patients, MRD\u2010positivity was associated with significantly shorter distant metastasis\u2010free survival (DMFS; hazard ratio [HR], 10.77; <jats:italic>p<\/jats:italic>\u00a0=\u00a0.01). Increasing ctDNA levels from the post\u2010surgical or pre\u2010treatment time point to after 6\u00a0weeks of ICI were predictive of shorter DMFS in cohort A (HR, 34.54; <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a0.0001) and shorter progression\u2010free survival (PFS) in cohort B (HR,\u00a022; <jats:italic>p<\/jats:italic>\u00a0=\u00a0.006). In cohort C, all ctDNA\u2010negative patients remained progression\u2010free for a median follow\u2010up of 14.67\u00a0months, whereas ctDNA\u2010positive patients experienced disease progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Personalized and tumor\u2010informed longitudinal ctDNA monitoring is a valuable prognostic and predictive tool that may be used throughout the clinical course of patients with advanced melanoma.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.34716","type":"journal-article","created":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T04:18:42Z","timestamp":1677903522000},"page":"1723-1734","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Circulating tumor DNA\u2010based molecular residual disease detection for treatment monitoring in advanced melanoma patients"],"prefix":"10.1002","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2307-7030","authenticated-orcid":false,"given":"Zeynep","family":"Eroglu","sequence":"first","affiliation":[{"name":"Department of Cutaneous Oncology Moffitt Cancer Center  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifra","family":"Krinshpun","sequence":"additional","affiliation":[{"name":"Natera, Inc  Austin Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Kalashnikova","sequence":"additional","affiliation":[{"name":"Natera, Inc  Austin Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumedha","family":"Sudhaman","sequence":"additional","affiliation":[{"name":"Natera, Inc  Austin Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turkan","family":"Ozturk Topcu","sequence":"additional","affiliation":[{"name":"Department of Cutaneous Oncology Moffitt Cancer Center  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Nichols","sequence":"additional","affiliation":[{"name":"Department of Cutaneous Oncology Moffitt Cancer Center  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Cutaneous Oncology Moffitt Cancer Center  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Bui","sequence":"additional","affiliation":[{"name":"Department of Cutaneous Oncology Moffitt Cancer Center  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3850-260X","authenticated-orcid":false,"given":"Charuta C.","family":"Palsuledesai","sequence":"additional","affiliation":[{"name":"Natera, Inc  Austin Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Natera, Inc  Austin Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry","family":"Olshan","sequence":"additional","affiliation":[{"name":"Natera, Inc  Austin Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Markowitz","sequence":"additional","affiliation":[{"name":"Department of Cutaneous Oncology Moffitt Cancer Center  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil I.","family":"Khushalani","sequence":"additional","affiliation":[{"name":"Department of Cutaneous Oncology Moffitt Cancer Center  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad A.","family":"Tarhini","sequence":"additional","affiliation":[{"name":"Department of Cutaneous Oncology Moffitt Cancer Center  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane L.","family":"Messina","sequence":"additional","affiliation":[{"name":"Department of Cutaneous Oncology Moffitt Cancer Center  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Aleshin","sequence":"additional","affiliation":[{"name":"Natera, Inc  Austin Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6660571"},{"key":"e_1_2_9_3_1","unstructured":"American Cancer Society.Cancer Facts & Figures 2022. Accessed October 15 2022.https:\/\/www.cancer.org\/research\/cancer\u2010facts\u2010statistics\/all\u2010cancer\u2010facts\u2010figures\/cancer\u2010facts\u2010figures\u20102022"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(14)70051\u20108"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx339"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1904059"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(19)30388\u20102"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.15_suppl.9506"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1910836"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(18)31559\u20109"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.06.028"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0018"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(17)30171\u20107"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010020\u201000509\u2010z"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.64.0391"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.004"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_320301"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00198"},{"issue":"1","key":"e_1_2_9_19_1","first-page":"207","article-title":"Melanoma radiological surveillance: a review of current evidence and clinical challenges","volume":"93","author":"Howard MD","year":"2020","journal-title":"Yale J Biol Med"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434\u2010019\u201007311\u20100"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40644\u2010021\u201000440\u20104"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2020.1731942"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416\u2010018\u20100167\u2010x"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.642380"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.09.019"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(20)30726\u20109"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz048"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201019\u20103926"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx026"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018\u2010020\u20100096\u20105"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/cmr.0000000000000628"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15088"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0528"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010021\u201003642\u20109"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010019\u201053636\u2010x"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.06.024"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30593"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.11.026"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110637"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx717"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.914"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.4_suppl.009"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.mct\u201017\u20100386"},{"key":"e_1_2_9_44_1","article-title":"Positive association between location of melanoma, ultraviolet signature, tumor mutational burden, and response to anti\u2010PD\u20101 therapy","volume":"5","author":"Dousset L","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.748674"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425\u2010019\u20100659\u20100"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.34716","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.34716","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.34716","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T18:56:50Z","timestamp":1760295410000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.34716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,4]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1002\/cncr.34716"],"URL":"https:\/\/doi.org\/10.1002\/cncr.34716","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,4]]},"assertion":[{"value":"2022-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}